

# CJASN

Clinical Journal of the American Society of Nephrology

May 2015 • Vol. 10 • No. 5

## Editorials

---

**723 Hemostatic Factors, *APOL1*, and ESRD Risk: Another Piece of the Puzzle?**

Walter G. Wasser and Ety Kruzel-Davila  
See related article on page 784.

**726 Evolving Calciphylaxis—What Randomized, Controlled Trials Can Contribute to the Capture of Rare Diseases**

Markus Ketteler and Patrick H. Biggar  
See related article on page 800.

**729 Posthemodialysis Weights and Mortality: Another Narrow Range Target?**

Kristen L. Jablonski and Michel Chonchol  
See related article on page 808.

## Original Articles

---

### Chronic Kidney Disease

**732 Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis**

Rupert W. Major, Chee Kay Cheung, Laura J. Gray, and Nigel J. Brunskill

**740 Association of Serum Ig Free Light Chains with Mortality and ESRD among Patients with Nondialysis-Dependent CKD**

James Ritchie, Lakhvir K. Assi, Anne Burmeister, Richard Hoefield, Paul Cockwell, and Philip A. Kalra

### Clinical Nephrology

**750 Clinicopathologic Characteristics and Outcomes of Renal Thrombotic Microangiopathy in Anti-Neutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis**

Su-Fang Chen, Huan Wang, Yi-Min Huang, Zhi-Ying Li, Su-Xia Wang, Feng Yu, Ming-Hui Zhao, and Min Chen

**759 Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease**

Elena M. Yubero-Serrano, Mark Woodward, Leonid Poretsky, Helen Vlassara, and Gary E. Striker on behalf of AGE-less Study Group

### Epidemiology and Outcomes

**767 Mineral Metabolism in European Children Living with a Renal Transplant: A European Society for Paediatric Nephrology/European Renal Association–European Dialysis and Transplant Association Registry Study**

Marjolein Bonthuis, Marco Busutti, Karlijn J. van Stralen, Kitty J. Jager, Sergey Baikov, Sevcan Bakkaloğlu, Nina Battelino, Maria Gaydarova, Bruno Gianoglio, Paloma Parvex, Clara Gomes, James G. Heaf, Ludmila Podracka, Dafina Kuzmanovska, Maria S. Molchanova, Tatiana E. Pankratenko, Fotios Papachristou, György Reusz, Maria José Sanahuja, Rukshana Shroff, Jaap W. Groothoff, Franz Schaefer, and Enrico Verrina

**776  Plasma Urate and Risk of a Hospital Stay with AKI: The Atherosclerosis Risk in Communities Study**

Keiko I. Greenberg, Mara A. McAdams-DeMarco, Anna Köttgen, Lawrence J. Appel, Josef Coresh, and Morgan E. Grams

**784 Hemostatic Factors, *APOL1* Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study**

Adrienne Tin, Morgan E. Grams, Nisa M. Maruthur, Brad C. Astor, David Couper, Thomas H. Mosley, Myriam Fornage, Rulan S. Parekh, Josef Coresh, and Wen Hong Linda Kao  
See related editorial on page 723.

### ESRD and Chronic Dialysis

- 791 The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial**  
*Patrick S. Parfrey, Tilman B. Drüeke, Geoffrey A. Block, Ricardo Correa-Rotter, Jürgen Floege, Charles A. Herzog, Gerard M. London, Kenneth W. Mahaffey, Sharon M. Moe, David C. Wheeler, Yumi Kubo, Bastian Dehmel, William G. Goodman, and Glenn M. Chertow for the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*
- 800 The Effect of Cinacalcet on Calcific Uremic Arteriopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial**  
*Jürgen Floege, Yumi Kubo, Anna Floege, Glenn M. Chertow, and Patrick S. Parfrey*  
*See related editorial on page 726.*
- 808 Associations of Posthemodialysis Weights above and below Target Weight with All-Cause and Cardiovascular Mortality**  
*Jennifer E. Flythe, Abhijit V. Kshirsagar, Ronald J. Falk, and Steven M. Brunelli*  
*See related editorial on page 729.*
- 817 Outcomes of Infection-Related Hospitalization according to Dialysis Modality**  
*Louis-Philippe Laurin, Hind Harrak, Naoual Elftouh, Denis Ouimet, Michel Vallée, and Jean-Philippe Lafrance*

### Genetics

- 825 Clinical and Molecular Characterization of Patients with Heterozygous Mutations in Wilms Tumor Suppressor Gene 1**  
*Anja Lehnhardt, Claartje Karnatz, Thurid Ahlenstiel-Grunow, Kerstin Benz, Marcus R. Benz, Klemens Budde, Anja K. Büscher, Thomas Fehr, Markus Feldkötter, Norbert Graf, Britta Höcker, Therese Jungraithmayr, Günter Klaus, Birgit Koehler, Martin Konrad, Birgitta Kranz, Carmen R. Montoya, Dominik Müller, Thomas J. Neuhaus, Jun Oh, Lars Pape, Martin Pohl, Brigitte Royer-Pokora, Uwe Querfeld, Reinhard Schneppenheim, Hagen Staude, Giuseppina Spartà, Kirsten Timmermann, Frauke Wilkening, Simone Wygoda, Carsten Bergmann, and Markus J. Kemper*

### Geriatric Nephrology

- 832 Frailty and Mortality in Dialysis: Evaluation of a Clinical Frailty Scale**  
*Talal A. Alfaadhel, Steven D. Soroka, Bryce A. Kiberd, David Landry, Paige Moorhouse, and Karthik K. Tennankore*

### Nephrolithiasis

- 842 CKD and Its Risk Factors among Patients with Cystinuria**  
*Caroline Prot-Bertoye, Saïd Lebbah, Michel Daudon, Isabelle Tostivint, Pierre Bataille, Franck Bridoux, Pierre Brignon, Christian Choquet, Pierre Cochat, Christian Combe, Pierre Conort, Stéphane Decramer, Bertrand Doré, Bertrand Dussol, Marie Essig, Nicolas Gaunez, Dominique Joly, Sophie Le Toquin-Bernard, Arnaud Méjean, Paul Meria, Denis Morin, Hung Viet N'Guyen, Christian Noël, Michel Normand, Michel Pietak, Pierre Ronco, Christian Saussine, Michel Tsimaratos, Gérard Friedlander, Olivier Traxer, Bertrand Knebelmann, and Marie Courbebaisse on behalf of the French Cystinuria Group*

## Renal Physiology

---

- 852 Osmotic Homeostasis**  
*John Danziger and Mark L. Zeidel*

## Role of the Medical Director

---

- 863 Infection Prevention and the Medical Director: Uncharted Territory**  
*Toros Kapoian, Klemens B. Meyer, and Douglas S. Johnson*

## In-Depth Review

---

### 875 Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup

Brian S. Decker, David S. Goldfarb, Paul I. Dargan, Marjorie Friesen, Sophie Gosselin, Robert S. Hoffman, Valéry Lavergne, Thomas D. Nolin, and Marc Ghannoum on behalf of the EXTRIP Workgroup

## Public Policy Series

---

### 888 How the ESRD Quality Incentive Program Could Potentially Improve Quality of Life for Patients on Dialysis

Alvin H. Moss and Sara N. Davison

## Special Features


---

### 894 Cross-Disciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium

Chi-yuan Hsu, Shawn Ballard, Daniel Batlle, Joseph V. Bonventre, Erwin P. Böttinger, Harold I. Feldman, Jon B. Klein, Josef Coresh, John H. Eckfeldt, Lesley A. Inker, Paul L. Kimmel, John W. Kusek, Kathleen D. Liu, Michael Mauer, Theodore E. Mifflin, Mark E. Molitch, Gary L. Nelsestuen, Casey M. Rebholz, Brad H. Rovin, Venkata S. Sabbiseti, Jennifer E. Van Eyk, Ramachandran S. Vasan, Sushrut S. Waikar, Krista M. Whitehead, and Robert G. Nelson for the CKD Biomarkers Consortium

### 903 American Society of Nephrology Quiz and Questionnaire 2014: Transplantation

Michelle A. Josephson, Mark A. Perazella, and Michael J. Choi

 eJournal club provides a timely and interactive electronic journal club experience by offering a forum in which CJASN readers have the opportunity to converse with the featured study authors. Visit [ejc.cjasn.org](http://ejc.cjasn.org) to learn more.

### On the Cover

*What's the diagnosis?* Kidney biopsy from a patient with acute kidney injury that developed in the setting of sepsis, multiple antibiotic exposure and rhabdomyolysis revealed findings consistent with myoglobinuric acute tubular injury/necrosis. The upper panel reveals acute tubular injury accompanied by intraluminal myoglobin casts. In the lower panel, immunohistochemical staining of the tubular casts is positive for myoglobin. Myoglobin is a heme pigment-containing protein released from injured muscle in the setting of traumatic or non-traumatic rhabdomyolysis. Myoglobin enters the urinary space via glomerular filtration whereupon the protein is degraded and heme pigment is released. While somewhat controversial, myoglobinuria is speculated to cause acute kidney injury through 3 possible mechanisms. These include direct tubular toxicity, tubular obstruction, and intra-renal vasoconstriction with reduced blood flow to the outer medulla. Importantly, myoglobin-associated heme pigment rarely causes kidney injury in the absence of other risk factors such as volume depletion and/or hypotension, which are associated with ischemic tubular injury and further perpetuate myoglobin cast formation. Acidic urine may also enhance toxicity by increasing cast formation, and facilitating the conversion of myoglobin to ferriheme (or heme), which may be more nephrotoxic. Prevention of kidney injury in the setting of rhabdomyolysis with myoglobinuria includes volume repletion to correct both hypovolemia and hypotension while also preventing myoglobin cast formation by producing brisk urine flow rates. While theoretical benefits to bicarbonate-containing intravenous fluids to prevent myoglobin-induced kidney injury exist, there are limited clinical data to support this fluid over intravenous isotonic saline. In addition, metabolic alkalosis can potentially worsen hypocalcemia, which is often associated with rhabdomyolysis, and promote calcium-phosphate deposition in the kidneys. Loop diuretics do not prevent myoglobin-associated AKI, but should be utilized in patients that develop hypervolemia. Some patients may require renal replacement therapy to manage AKI, the associated metabolic abnormalities, and hypervolemia. Most patients recover from AKI, although CKD may be a long-term complication. (Images and text provided by Mark A. Perazella, MD, Yale University School of Medicine, New Haven, Connecticut, and Glen S. Markowitz, MD, Columbia University College of Physicians and Surgeons, New York)